Question explored with the scientific record
Conversation so far
- 1 what can help slow down or prevent dementia
- 2 so theres no way to cure or improve dementia?
Answered on this page ↓
so theres no way to cure or improve dementia?
The short version: there is no cure for dementia, and the evidence for disease-modifying treatments is thin, conflicted, or limited to modest slowing in narrow subgroups.
The only drug with a phase 3 trial showing a statistically significant effect on cognitive decline is lecanemab, and the effect is tiny. On the primary endpoint (CDR-SB, a 0–18 scale of function), the difference from placebo after 18 months was -0.45 points [1]. That is less than half a point on an 18-point scale. The drug also carries real risks: ARIA-E (brain swelling) occurred in 12.6% of treated patients versus 1.7% of placebo, and ARIA-H (brain microbleeds) in 16.9% versus 8.9% [1]. APOE4 homozygotes had the worst safety profile, with ARIA-H in 38.3% [1]. The trial was funded by the manufacturer (Eisai/Biogen). No long-term data beyond the open-label extension exists.
For vascular dementia, the evidence is even weaker. A rat study of PPAR-gamma agonists showed cognitive improvement [18], and a rat study of acupuncture showed LTP restoration [19]. Neither has been replicated in humans. The semagacestat trial (a gamma-secretase inhibitor) actually made patients worse: higher doses increased neuropsychiatric symptoms and cognitive decline [5, 7]. That is a failed drug, not a treatment.
The reversible causes are real but rare. In one early-onset dementia cohort, infectious causes (neurosyphilis, CJD) accounted for a small fraction of cases [14]. Inflammatory and vascular causes are also occasionally reversible if caught early [15]. But for the vast majority of Alzheimer's, Lewy body, and frontotemporal dementias, no disease-modifying therapy exists.
| Intervention | Population | Effect size | Key risk |
|---|---|---|---|
| Lecanemab | Early Alzheimer's | CDR-SB -0.45 at 18 months [1] | ARIA-E 12.6%, ARIA-H 16.9% |
| Semagacestat | Mild-moderate AD | Worsened cognition and NPS [5, 7] | Increased neuropsychiatric symptoms |
| PPAR-gamma agonists | Rat vascular dementia | Improved cognition [18] | Not tested in humans |
| Acupuncture | Rat vascular dementia | Improved LTP [19] | Not tested in humans |
My call: for the common dementias, there is no cure and no treatment that clearly slows progression beyond a trivial amount. The lecanemab effect is real but clinically marginal and comes with serious brain safety risks. Confidence: high that no disease-modifying cure exists; moderate that lecanemab provides a real but very small benefit for a narrow subgroup.
Sources examined 29
-
Krankheitsmodifizierende Therapie mit Lecanemab bei früher Alzheimer-Demenz
Lecanemab appears to modestly slow cognitive and functional decline in early Alzheimer's disease with biomarker evidence of disease modification, but carries safety risks (ARIA, APOE4-associated) and high costs that demand careful patient selection and monitoring, as shown in CL…
DOI: 10.1055/a-2681-4558 -
Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease
APOE ε4 status shapes the clinical, biomarker and neuroimaging phenotype of prodromal Alzheimer's disease, with APOE ε4-negative individuals showing more dysexecutive decline, higher CSF Aβ and axonal injury markers, greater white matter pathology and cortical atrophy, and faste…
DOI: 10.1016/J.NEUROBIOLAGING.2018.07.003 -
PS2APP Transgenic Mice, Coexpressing hPS2mut and hAPPswe, Show Age-Related Cognitive Deficits Associated with Discrete Brain Amyloid Deposition and Inflammation
Age-related cognitive decline in PS2APP transgenic mice coexpressing mutant PS2 and APP emerges alongside region-specific amyloid deposition and inflammation, illustrating a link between discrete plaque formation and cognitive impairment.
DOI: 10.1523/jneurosci.23-26-08989.2003 -
Oral prodrug of a novel glutathione surrogate reverses metabolic dysregulation and attenuates neurodegenerative process in APP/PS1 mice
This study demonstrates that the oral prodrug pro-ψ-GSH effectively reverses cognitive decline and mitigates neurodegenerative processes in APP/PS1 mice by restoring glyoxalase-1 activity and reducing oxidative stress and amyloid pathology.
DOI: 10.1101/2025.01.15.633247 -
Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease
This study investigates the neuropsychiatric effects of semagacestat treatment in Alzheimer's disease, revealing that higher doses are associated with increased neuropsychiatric symptoms and cognitive decline.
DOI: 10.3233/jad-151113 -
Parkinson disease-associated cognitive impairment
This Nature Reviews Disease Primers article provides a comprehensive, evidence-based overview of Parkinson disease–associated cognitive impairment, covering its epidemiology, mechanisms, biomarkers, diagnostic criteria, and current/nonpharmacological and pharmacological manageme…
DOI: 10.1038/s41572-021-00280-3 -
Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer’s Disease
A large secondary analysis of a 76-week phase III trial in mild-to-moderate Alzheimer’s disease shows that high-dose semagacestat increases neuropsychiatric symptoms (notably appetite, aberrant motor behavior, depression, and sleep) and that incident neuropsychiatric changes are…
DOI: 10.3233/JAD-151113 -
Progression of mild Alzheimer’s disease: knowledge and prediction models required for future treatment strategies
A three-year, real-world, prospective study of cholinesterase inhibitor therapy in 734 adults with mild Alzheimer's disease shows that instrumental activities of daily living decline faster than cognition or global measures; higher mean ChEI dose and lower education predict slow…
DOI: 10.1186/alzrt210 -
Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies
A comprehensive review detailing how Parkinson's disease dementia (PDD) likely arises from the convergence and interaction of three core neuropathologies—α-synuclein, tau, and amyloid-β—across genetic, clinical, and biomarker dimensions, and outlining their implications for diag…
DOI: 10.1038/nrn3549 -
Metabotropic glutamate receptors: the potential for therapeutic applications in Alzheimer's disease
A comprehensive review evaluating how metabotropic glutamate receptors (Group I–III mGluRs) influence Alzheimer's disease pathology and the potential of allosteric modulators (NAMs, PAMs, NALs) to provide symptomatic and disease-modifying therapies, with emphasis on mGlu5 and mG…
DOI: 10.1016/j.coph.2017.12.001 -
Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS)
A 22-year prospective cohort study of Caerphilly men showing regular benzodiazepine use is associated with a substantially increased long-term risk of dementia (vascular and non-vascular), with no clear dose–response and results largely robust to adjustment for distress/anxiety,…
DOI: 10.1136/JECH-2011-200314 -
Causal associations between cognitive impairments and retinal diseases: A two-sample Mendelian randomization study
Using bidirectional two-sample Mendelian randomization on large European-ancestry GWAS datasets, this study investigates causal links between cognitive impairments (Alzheimer's disease, Lewy body dementia, vascular dementia) and retinal diseases, finding inverse associations fro…
DOI: 10.1177/03000605251404265 -
The effect of type 2 diabetes genetic predisposition on non-cardiovascular comorbidities
Using bidirectional and cluster-stratified Mendelian randomization across multi-ancestry GWAS data and a mechanistic clustering of type 2 diabetes (T2D) genetic risk, the study provides evidence that T2D genetic predisposition causally influences several non-cardiovascular comor…
DOI: 10.1038/s41467-025-64927-5 -
PO23-TH-07 Stroke health service development program (HSDP): screening for post stroke dementia
The study investigates the diverse etiologies of early-onset dementia, highlighting the differences in causes based on age of onset and emphasizing the need for thorough investigations for potentially reversible conditions.
DOI: 10.1016/s0022-510x(09)71064-0 -
Baseline differences between vascular cognitive impairment no dementia reverters and non-reverters
This study investigates the demographic, cognitive, and imaging factors that differentiate Vascular Cognitive Impairment, No Dementia (Vascular CIND) patients who revert to normal cognitive functioning from those who do not, finding that non-reverters exhibit greater cognitive i…
DOI: 10.1136/jnnp.2007.137554 -
Metabolic dysfunction-associated steatotic liver disease, metabolic alcohol-related liver disease, and incident dementia: a nationwide cohort study
This nationwide cohort study investigates the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic alcohol-related liver disease (MetALD) with the risk of developing dementia, revealing that MASLD is linked to increased risks of Alzh…
DOI: 10.1186/s12876-025-03814-1 -
Polysomnographic abnormalities in patients with vascular cognitive impairment-no dementia
This study compared subjective sleep quality and overnight polysomnography across VCIND patients, simple stroke patients, and controls, finding VCIND associated with worse sleep quality, longer sleep latency, lower sleep efficiency, more arousals and periodic limb movements, and…
DOI: 10.1016/j.sleep.2013.07.003 -
Behavioral and biochemical investigations to explore pharmacological potential of PPAR-gamma agonists in vascular dementia of diabetic rats
In STZ-induced diabetic rats modeling vascular dementia, the study demonstrates that PPAR-γ agonists pioglitazone and rosiglitazone, as well as donepezil, improve learning and memory, vascular endothelial function, reduce oxidative stress and brain acetylcholinesterase activity,…
DOI: 10.1016/j.pbb.2011.08.020 -
Acupuncture Attenuated Vascular Dementia–Induced Hippocampal Long-Term Potentiation Impairments via Activation of D1/D5 Receptors
In a rat model of vascular dementia, acupuncture at GV20 and ST36 improves hippocampal long-term potentiation and cognitive performance by increasing hippocampal dopamine release and activating D1/D5 receptors, an effect blocked by the D1/D5 antagonist SCH23390.
DOI: 10.1161/STROKEAHA.116.014696 -
A Meta-Analysis of Neuropsychological Functioning in the Logopenic Variant of Primary Progressive Aphasia: Comparison with the Semantic and Non-Fluent Variants
This meta-analysis establishes the neuropsychological profile of the logopenic variant of primary progressive aphasia (lvPPA) and compares it to the semantic and non-fluent variants, revealing significant deficits in attention, math, visuospatial memory, and executive functionin…
DOI: 10.1017/S1355617719001115 -
Intensive training of phonological skills in progressive aphasia: A model of brain plasticity in neurodegenerative disease
Three patients with nonfluent primary progressive aphasia underwent intensive phonological training with temporally slowed speech, showing selective improvements in fluency, reading, and repetition in some domains, indicating brain plasticity despite neurodegeneration.
DOI: 10.1016/s0278-2626(01)80065-8 -
Abnormal laughter-like vocalisations replacing speech in primary progressive aphasia
This study describes a syndrome of abnormal laughter-like vocalizations that replace speech in patients with primary progressive aphasia, highlighting its acoustic characteristics and potential underlying neural mechanisms.
DOI: 10.1016/j.jns.2009.04.021 -
Semantic Dementia and Primary Progressive Aphasia: A Problem of Categorization?
This study explores the relationship between semantic dementia and primary progressive aphasia, arguing that semantic dementia is a distinct syndrome characterized by specific deficits in conceptual knowledge rather than language alone.
DOI: 10.1097/01.wad.0000183085.22562.13 -
White matter damage in primary progressive aphasias: a diffusion tensor tractography study
This study investigates white matter damage in primary progressive aphasia variants using diffusion tensor imaging, revealing distinct patterns of white matter changes associated with each variant.
DOI: 10.1093/brain/awr099 -
Prominent hypometabolism of the right temporoparietal and frontal cortex in two left-handed patients with primary progressive aphasia
This study investigates cerebral glucose metabolism in two left-handed patients with primary progressive aphasia (PPA) using F-18 FDG PET imaging, revealing significant right-hemispheric hypometabolism that challenges the traditional view of PPA as primarily a left-hemisphere di…
DOI: 10.1007/s00415-002-0832-z -
Logopenic aphasia in Alzheimer's disease: clinical variant or clinical feature?
This study investigates whether patients with clinically typical early-stage Alzheimer's disease exhibit a language disorder resembling logopenic aphasia, finding that while some linguistic impairments are present, they do not consistently align with the profiles of primary prog…
DOI: 10.1136/jnnp-2012-302798 -
Evaluation of the New Consensus Criteria for the Diagnosis of Primary Progressive Aphasia Using Fluorodeoxyglucose Positron Emission Tomography
This study evaluates the correlation between clinical diagnoses of primary progressive aphasia (PPA) using new consensus criteria and brain topography as assessed by fluorodeoxyglucose positron emission tomography (FDG-PET), finding a high correlation but noting an overdiagnosis…
DOI: 10.1159/000358233 -
Familial language network vulnerability in primary progressive aphasia
This study investigates the familial language network vulnerability in primary progressive aphasia (PPA) by examining a proband and her nine siblings, revealing significant cognitive discrepancies and decreased connectivity in language-related brain regions.
DOI: 10.1212/WNL.0000000000009842 -
Different patterns of Mini Mental Status Examination responses in primary progressive aphasia and Alzheimer's disease
This study investigates the differences in Mini Mental Status Examination (MMSE) responses between patients with primary progressive aphasia (PPA) and Alzheimer's disease (AD), finding that specific item scores can help differentiate between the two conditions in early stages.
DOI: 10.1111/j.1468-1331.2006.01455.x